Pershing Edward 4

What Happened

• Edward Pershing, CEO and Director of Provectus Biopharmaceuticals (PVCT), reported an acquisition-type derivative award on 2026-03-25. The Form 4 lists "N/A" shares at $0.00 (transaction code A), indicating receipt of a convertible instrument rather than immediate common stock.
• The filing shows no common shares or dollar value received. The underlying instrument is an 8% unsecured convertible promissory note issued under the company's 2025 financing, with rights to convert into Series D‑1 Convertible Preferred Stock.

Key Details

• Transaction date: 2026-03-25; Form 4 filed 2026-03-26 (timely filing).
• Reported transaction: Award/acquisition of a derivative (convertible promissory note) — no common share count or immediate cash value reported (N/A / $0.00).
• Conversion terms (from footnotes):
  • The Note may be voluntarily converted into Series D‑1 Preferred Stock at $2.862 per Series D‑1 share while the Note is outstanding.
  • The Note will automatically convert into Series D‑1 shares 12 months after the Note’s issue date.
  • Each Series D‑1 Preferred share is convertible into 10 shares of common stock; Series D‑1 will automatically convert into common on December 31, 2028 unless converted earlier.
• Shares owned after transaction: not reported on the Form 4.
• Transaction code: A = Award/other acquisition (derivative). No 10b5-1, tax withholding, or late-filing notes were indicated in the filing.

Context

• This was an acquisition of a convertible instrument (note/preferred) rather than a direct buy of common stock. It does not represent immediate ownership of common shares; conversion events and timing will determine any future common-stock dilution.
• For retail investors, such derivatives can lead to future issuance of preferred and then common shares (potential dilution) but do not by themselves signal an immediate change in insider common-stock holdings or a direct bullish/bearish sale.